Skip to main content
SpringerLink
Log in

Rheumatologisch bedingte neurologische Erkrankungen

Wesentliche Berührungspunkte der Fachgebiete

  • CME Fortbildung
  • Published:
CME Aims and scope

Zusammenfassung

Rheumatische Erkrankungen führen über systemische Entzündungsreaktionen oft zu einer Beteiligung des peripheren oder zentralen Nervensystems und der Muskulatur. Daher ist es bei neu aufgetretenen neurologischen Symptomen wichtig, in der Differenzialdiagnostik auch rheumatologische Erkrankungen zu berücksichtigen. Dieser Artikel gibt eine Übersicht über neurologische Störungen, die ihren Ursprung in systemischen rheumatologischen Erkrankungen haben können.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© M. Maschke

2

© M. Maschke

3

© M. Maschke

4

© Nach M. Maschke

5

© M. Maschke

Literatur

  1. Badley EM. Rheumatic diseases: the unnoticed elephant in the room. J Rheumatol 2008;35:6-7

  2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11

  3. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389:2338-48

  4. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328-37

  5. Salliot C, Nguyen Y, Boutron-Ruault MC, Seror R. Environment and Lifestyle:Their Influence on the Risk of RA. J Clin Med 2020;9:3109

  6. Maschke M, Weiner SM. Rheumatologisch bedingte neurologische Erkrankungen. Aktuelle Neurologie 2015;42:212-7

  7. Westhoff G, Schneider M, Raspe H et al. Advance and unmet need of health care for patients with rheumatoid arthritis in the German population-results from the German Rheumatoid Arthritis Population Survey (GRAPS). Rheumatology 2009;48:650-7

  8. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19

  9. Furst DE, Emery P. Rheumatoid arthritis pathophysiology:update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 2014;53:1560-9

  10. Suwannalai P, Trouw LA, Toes RE et al. Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Mod Rheumatol 2012;22:15-20

  11. Reed E, Hedström AK, Hansson M, et al. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther 2020;22:170

  12. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81

  13. Fiehn C, Holle J, Iking-Konert C, et al. S2e guideline:treatment of rheumatoid arthritis with disease-modifying drugs. Z Rheumatol 2018;77(Suppl 2):35-53

  14. Schneider M, Baseler G, Funken O et al. Interdisziplinäre Leitlinie Management der frühen rheumatoiden Arthritis;https://www.awmf.org/uploads/tx_szleitlinien/060-002l_S3_Fruehe_Rheumatoide-Arthritis-Management_2019-12_01.pdf

  15. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13

  16. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases:What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis 2018;77:175-87

  17. Ramos-Remus C, Duran-Barragan S, Castillo-Ortiz JD. Beyond the joints: neurological involvement in rheumatoid arthritis. Clin Rheumatol 2012;31:1-12

  18. DeQuattro K, Imboden JB. Neurologic Manifestations of Rheumatoid Arthritis. Rheum Dis Clin North Am 2017;43:561-71

  19. Hamed SA, Selim ZI, Elattar AM, Elserogy YM, Ahmed EA, Mohamed HO. Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis. Clin Rheumatol 2012;31:123-32

  20. Baerwald C, Manger B, Hueber A. Depression as comorbidity of rheumatoid arthritis. Z Rheumatol 2019;78:243-8

  21. Brüggemann N, Gottschalk S, Holl-Ulrich K, Stewen J, Heide W, Seidel G. Cranial pachymeningitis:a rare neurological syndrome with heterogeneous aetiology. J Neurol Neurosurg Psychiatry 2010;81:294-8

  22. Cianfoni A, Falcone C, Faustini F, Lauriola L, Imbesi S, Della Marca G, Zoli A, Colosimo C. Rheumatoid leptomeningitis:magnetic resonance imaging and pathologic findings - a case report. J Neuroimaging 2010;20:192-4

  23. Manolios E, Manolios N, Spencer D. Leptomeningitis in rheumatoid arthritis. Eur J Rheumatol. 2020; doi:10.5152/eurjrheum.2020.20063

  24. Agarwal V, Singh R, Wiclaf et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol 2008;27:841-4

  25. Weller RO, Bruckner FE, Chamberlain MA. Rheumatoid neuropathy: a histological and electrophysiological study. J Neurol Neurosurg Psychiatry 1970;33:592-604

  26. Kaeley N, Ahmad S, Pathania M, Kakkar R. Prevalence and patterns of peripheral neuropathy in patients of rheumatoid arthritis. J Family Med Prim Care 2019;8:22-6

  27. Ahmed Z, Powell R, Llewelyn G, Anstey A. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis. BMJ Case Rep 2011; pii:bcr0820114674

  28. Patwala K, Crump N, De Cruz P. Guillain-Barré syndrome in association with antitumour necrosis factor therapy:a case of mistaken identity. BMJ Case Rep 2017; bcr2017219481

  29. Naranjo A, Carmona L, Gavrila D, Balsa A, Belmonte MA, Tena X, Rodríguez-Lozano C, Sanmartí R, González-Alvaro I; EMECAR Study Group. Prevalence and associated factors of anterior atlantoaxial luxation in a nationwide sample of rheumatoid arthritis patients. Clin Exp Rheumatol 2004;22:427-32

  30. Watson P, Fekete J, Deck J. Central nervous system vasculitis in rheumatoid arthritis. Can J Neurol Sci 1977;4:269-72

  31. Neamtu L, Belmont M, Miller DC, et al. Rheumatoid disease of the CNS with meningeal vasculitis presenting with a seizure. Neurology 2001;56:814-5

  32. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 2018;30:144-50

  33. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018;32:188-205

  34. Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151-9

  35. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608

  36. Borowoy AM, Pope JE, Silverman E et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012;42:179-85

  37. Jeltsch-David H, Muller S.Neuropsychiatric systemic lupus erythematosus:pathogenesis and biomarkers. Nat Rev Neurol 2014;10:579-96

  38. Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012;259:622-9

  39. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553-8

  40. van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, Bultink IE. Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus 2013;22:1462-9

  41. Schwarting A, Möckel T, Lütgendorf F, et al. Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies. Ann Rheum Dis 2019;78:1226-34

  42. Katsiari CG, Vikelis M, Paraskevopoulou ES, Sfikakis PP, Mitsikostas DD. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache 2011;51:1398-407

  43. Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N, Sarrot-Reynauld F, Broussolle C, Sève P. Systemic lupus erythematosus-associated acute transverse myelitis:manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus 2015;24:74-81

  44. Böckle BC, Jara D, Aichhorn K et al. Cerebral large vessel vasculitis in systemic lupus erythematosus. Lupus 2014;23:1417-21

  45. Kato R, Sumitomo S, Kawahata K, Fujio K, Yamamoto K. Successful treatment of cerebral large vessel vasculitis in systemic lupus erythematosus with intravenous pulse cyclophosphamide. Lupus 2015;24:880-4

  46. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014;10:338-47

  47. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45

  48. Berlit P, Krämer M. S1-Leitlinie Zerebrale Vaskulitis und zerebrale Beteiligung bei systemischen Vaskulitiden und rheumatischen Grunderkrankungen. DGNeurologie 2018;1:17-37

  49. Schirmer JH, Aries PM, de Groot K, et al. S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 2017;76:77-104

  50. Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019;393:2332-43

  51. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365-71

  52. Cohen H, Cuadrado MJ, Erkan D, et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus 2020;29:1571-93

  53. Mariette X, Criswell LA. Primary Sjögren's Syndrome. N Engl J Med 2018;378:931-9

  54. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome:a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8

  55. Chai J, Logigian EL. Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 2010;23:509-13

  56. Goransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjogren syndrome:a population-based study. Arch Neurol 2006;63:1612-15

  57. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 2005;128:2518-34

  58. Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry 2006;77:967-9

  59. Kastrup O, Maschke M, Diener HC. Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome. Clin Neurol Neurosurg 2005;107:440-1

  60. RamosCasals M, Brito-Zerón P, Bombardieri S et al; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis 2020;79:3-18

  61. Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases:three case reports and a review of the literature. Ann Rheum Dis 2003;62:50-7

  62. Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin 2011;27:11-20

  63. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis & Rheumatism 2007;56:1125-33

  64. Zhang P, Li X, Li Y, Wang J, Zeng H, Zeng X. Biomed Rep. Reversible posterior leukoencephalopathy syndrome secondary to systemic-onset juvenile idiopathic arthritis: A case report and review of the literature. 2015;3:55-58

  65. Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag K, Winthrop KL, Curtis JR. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken) 2012;64:612-25

  66. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; BSRBR Control Centre Consortium, Symmons DP;BSR Biologics Register. Drugspecific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy:results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8

  67. Chan JW, Castellanos A. Infliximab and anterior optic neuropathy:case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010;248:283-7

  68. Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003;326:579

  69. von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica 2008;222:292-4

Download references

Author information

Authors and Affiliations

  1. Krankenhaus Barmherzige Brüder, Nordallee 1, 54292, Trier, Germany

    Matthias Maschke

  2. Abteilung Innere Medizin II, Trier, Germany

    Stefan M. Weiner

Authors
  1. Matthias Maschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan M. Weiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maschke, M., Weiner, S. Rheumatologisch bedingte neurologische Erkrankungen. CME 18, 61–70 (2021). https://doi.org/10.1007/s11298-021-1926-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11298-021-1926-1

Schlüsselwörter

Search

Navigation